William Blair Issues Positive Estimate for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Research analysts at William Blair upped their Q4 2024 earnings per share (EPS) estimates for shares of Medpace in a note issued to investors on Tuesday, October 22nd. William Blair analyst M. Smock now forecasts that the company will post earnings per share of $2.87 for the quarter, up from their prior forecast of $2.86. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.64 per share. William Blair also issued estimates for Medpace’s Q2 2025 earnings at $3.06 EPS.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.22 EPS.

MEDP has been the subject of several other reports. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and decreased their price target for the company from $420.00 to $350.00 in a report on Friday, September 27th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Robert W. Baird cut shares of Medpace from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $413.00 to $349.00 in a research report on Wednesday. Redburn Atlantic assumed coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective for the company. Finally, TD Cowen lowered their target price on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $380.00.

Medpace Price Performance

Medpace stock opened at $328.08 on Friday. The company has a market cap of $10.16 billion, a PE ratio of 33.44, a P/E/G ratio of 1.77 and a beta of 1.35. Medpace has a 12 month low of $239.00 and a 12 month high of $459.77. The company has a fifty day moving average price of $352.59 and a two-hundred day moving average price of $381.83.

Institutional Trading of Medpace

Several institutional investors have recently modified their holdings of MEDP. Sunbelt Securities Inc. boosted its position in shares of Medpace by 24.5% during the 1st quarter. Sunbelt Securities Inc. now owns 514 shares of the company’s stock valued at $208,000 after purchasing an additional 101 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Medpace by 16.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,340 shares of the company’s stock worth $4,179,000 after acquiring an additional 1,446 shares during the last quarter. State of Michigan Retirement System lifted its holdings in shares of Medpace by 1.8% during the first quarter. State of Michigan Retirement System now owns 5,699 shares of the company’s stock valued at $2,303,000 after purchasing an additional 100 shares during the last quarter. Norden Group LLC raised its holdings in Medpace by 488.0% during the 1st quarter. Norden Group LLC now owns 29,480 shares of the company’s stock worth $11,914,000 after buying an additional 24,466 shares during the period. Finally, Arcus Capital Partners LLC lifted its stake in Medpace by 15.7% during the first quarter. Arcus Capital Partners LLC now owns 965 shares of the company’s stock valued at $390,000 after buying an additional 131 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.